Page 270 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
Combination strategies for gastric cancer

therapy with paclitaxel (PTX), ramucirumab (RAM) plus doi: 10.4251/wjgo.v15.i1.69
nivolumab (Nivo) for advanced gastric cancer (AGC). Ann
Oncol. 2020;31:S282-S283. 9. Tan Y, Wang H, Xu B, et al. Chinese herbal medicine
combined with oxaliplatin-based chemotherapy for
doi: 10.1016/j.annonc.2020.08.225 advanced gastric cancer: A systematic review and meta-
7. Thuss-Patience P, Högner A, Goekkurt E, et al. analysis of contributions of specific medicinal materials to
Ramucirumab, avelumab, and paclitaxel as second-line tumor response. Front Pharmacol. 2022;13:977708.
treatment in esophagogastric adenocarcinoma: The phase
2 RAP (AIO-STO-0218) nonrandomized controlled trial. doi: 10.3389/fphar.2022.977708
JAMA Netw Open. 2024;7(1):e2352830. 10. Kong X, Li Q, Wang D, Wang M, Yang F, Meng J. Mechanism
doi: 10.1001/jamanetworkopen.2023.52830 of qizhen decoction-mediated maturation of DC cells
to activate the IL-12/JAK2/STAT4 pathway to sensitise
8. Ye HN, Liu XY, Qin BL. Research progress of integrated PD-1 inhibitors in the treatment of colorectal cancer.
traditional Chinese and Western medicine in the treatment J Ethnopharmacol. 2024;320:117399.
of advanced gastric cancer. World J Gastrointest Oncol.
2023;15(1):69-75. doi: 10.1016/j.jep.2023.117399

Volume 9 Issue 1 (2025) 262 doi: 10.36922/ejmo.8594